A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

SAN DIEGO — New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings ...

Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2 diabetes, with one clinically balanced definition linking drug use to reduced ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

SEATTLE -- GLP-1 receptor agonist use was tied with a reduced risk for fracture among older women with type 2 diabetes, a retrospective cohort study found. Among over 350,000 GLP-1 users, there was a ...

GLP-1 RA prescriptions were associated with greater protection against uveitis compared with the cohorts taking metformin and insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists (GLP ...